Advertisement


Saad Z. Usmani, MD: In My Experience Question 1

COVID-19 and Cancer Care

Advertisement

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.



Related Videos

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 3

COVID-19

Karen E. Knudsen, PhD, MBA, on Delivering Cancer Care During the COVID-19 Pandemic: Report From Philadelphia

Karen E. Knudsen, PhD, MBA, Director of the Sidney Kimmel Cancer Center, talks about what she and her staff have encountered during the COVID-19 crisis and how they and their patients are coping. Filmed March 25, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 5

For community oncologists treating patients with chronic myeloid leukemia or chronic lymphocytic leukemia during the COVID-19 pandemic, what resources and clinical pearls would you suggest?

Recorded April 24, 2020.

Hematologic Malignancies
COVID-19

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.

COVID-19
Global Cancer Care

Jacek Jassem, MD, PhD, on Fighting COVID-19 and Cancer: The View From Poland

Jacek Jassem, MD, PhD, of the Medical University of Gdansk, and an international editor on The ASCO Post Editorial Board, talks about the situation in Poland, how his institution is coping, and the adjustments the staff has made to deliver quality cancer care. Filmed April 17, 2020.

Advertisement

Advertisement




Advertisement